<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECT: <z:chebi fb="0" ids="29767">Nitroxides</z:chebi> mimic <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) biochemically and may prevent free radical oxidative injury in settings in which endogenous SOD is overwhelmed </plain></SENT>
<SENT sid="1" pm="."><plain>The authors have previously shown the efficacy of a <z:chebi fb="0" ids="29767">nitroxide</z:chebi>, Tempol, in reducing <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="2" pm="."><plain>Of the <z:chebi fb="0" ids="29767">nitroxides</z:chebi>, 3-<z:chebi fb="0" ids="23004,33100">carbamoyl</z:chebi>-proxyl (3-CP) is especially promising for clinical use, because it does not cause <z:hpo ids='HP_0002615'>hypotension</z:hpo> in animals </plain></SENT>
<SENT sid="3" pm="."><plain>Its efficacy in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>, however, is untested </plain></SENT>
<SENT sid="4" pm="."><plain>The goal of this study was to ascertain whether 3-CP would reduce brain damage in a rat <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion model </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: The authors performed a blinded, dose-response study of the effect of different amounts of 3-CP (1, 10, and 100 mg/kg) on <z:mpath ids='MPATH_124'>infarct</z:mpath> size at 24 hours after focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>The 3-CP was given intravenously during reperfusion, which followed 1 hour of reversible <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced by a thread placed intraluminally in the middle cerebral artery of rats </plain></SENT>
<SENT sid="7" pm="."><plain>Brain <z:mpath ids='MPATH_124'>infarcts</z:mpath>, measured with 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining in six 3-CP groups, were compared with those measured in controls (animals given an equal volume of saline) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000969'>Edema</z:hpo>-corrected <z:mpath ids='MPATH_124'>infarct</z:mpath> sizes (mean +/- standard deviation) were as follows: 146 +/- 64 mm3 in controls; 107 +/- 18 mm3 in rats given 1 mg/kg 3-CP; 40 +/- 20 mm3 in those given 10 mg/kg 3-CP; and 44 +/- 17 mm3 in those given 100 mg/kg 3-CP </plain></SENT>
<SENT sid="9" pm="."><plain>A statistically significant reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> size was achieved in the 10- and 100-mg/kg 3-CP-treated groups (p &lt; 0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>A reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> size was also seen in the 1 mg/kg 3-CP-treated group, but this did not reach statistical significance </plain></SENT>
<SENT sid="11" pm="."><plain>The authors observed no effects of 3-CP on blood pressure or brain temperature </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Given at reperfusion, 3-CP significantly decreases brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size at doses of 10 and 100 mg/kg without causing <z:hpo ids='HP_0002615'>hypotension</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>The authors found that 3-CP is well suited for further laboratory and clinical use in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> and reperfusion </plain></SENT>
</text></document>